Delivery Order SPE2DB24D1201-SPE2DB25FJDSQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,560.80 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $4,700.52 to AmerisourceBergen Drug Corp for Vemlidy 25 mg tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $2,981.76 delivery order to AmerisourceBergen Drug Corp for Vemlidy 25 mg tablets (30-count units) on July 22, 2025, with a completion date of July 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be fulfilled at the vendor's Conshohocken, Pennsylvania location. The delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,252.42 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation and is scheduled for completion by July 25, 2025,...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 18, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This firm fixed-price contract, valued at $15,138.05, represents a competitive award with no set-aside designation and an ultimate completion date of July 21, 2025. The award is classified as a child contract, indicating it derives from a larger prime contract vehicle. AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $10,710.30 for Vemlidy 25 mg tablets (30-count units) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $2,919.85 to AmerisourceBergen Drug Corp for Vemlidy 25 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Vemlidy is an antiviral medication used in the treatment of chronic hepatitis B, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $1,405.94 to AmerisourceBergen Drug Corp for 30 tablets of Vemlidy 25 mg on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance to be completed at the contractor's Conshohocken, Pennsylvania facility. The contract is a child award under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30 units, with a ceiling value of $3,176.22 and a completion date of July 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is executed as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global...
- The Defense Logistics Agency awarded a $3,914.21 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vemlidy 25 mg tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a non-set-aside competitive award representing a child order under AmerisourceBergen's larger contract vehicle with DLA. Vemlidy is an antiviral medication, and this delivery order reflects AmerisourceBergen's role as a critical pharmaceutical supplier supporting...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDSQDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,111.80 for Vemlidy 25 mg tablets (quantity: 30 units) on July 31, 2025, with an ultimate completion date of August 1, 2025. The contract employs firm fixed pricing and represents a non-set-aside, competitively awarded procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare systems and other federal agencies including the Defense Health Agency and U.S. Coast Guard. The DLA Troop Support Medical IDC enables the company to fulfill pharmaceutical requirements on a global basis, with the agency planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple regional awards and contractors. Vemlidy, an antiviral medication used in hepatitis B treatment, represents one of the specialized pharmaceutical products supplied under this comprehensive federal medical supply vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 7/31/25 |